Wu Bin, Wang Kai, Mo Chun-Ba, Shen Zhong-Yang
Department of Transplant Surgery, First Central Hospital Clinc Institute, Tianjin Medical University China ; Key Laboratory of Organ Transplant of Tianjin China.
Int J Clin Exp Med. 2015 Feb 15;8(2):2911-6. eCollection 2015.
Post-transplant malignancies are a major cause of morbidity and mortality after renal transplantation. This retrospective study investigated the incidence and outcome of de novo malignancies following kidney transplantation in a single China kidney transplantation center.
Between 1989 and 2010, 1467 patients underwent kidney transplantation at transplantation center of Tianjin First Central Hospital of Tianjin Medical University. Data were analyzed for tumor incidence, clinical characteristics, and outcome. A review of the literature is also summarized.
After 1,467 renal transplantations, 5 men and 9 women (sex ratio 5:9) with a mean age of 54 years (21-64) were included for malignancies, an overall incidence of 0.954%. Urinary tract malignancies represented the most frequent malignancies (57%). The time of postoperative tumor occurring varied from 1 to 133 months with an average value of 42.78 months. Among them, 4 died and the mortality rate was 28.6%.
In short, with the increasing of transplant patients and the prolonging of survival time with kidney, the occurrence of malignancies will be increasing. This requires that we should set up perfect transplant follow-up system, and do regular follow-up and careful physical examination, do not overlook any early feature of tumor, at last achieve early diagnosis of tumor, and early treatment to improve the cure rate of postoperative malignancies of renal transplantation.
移植后恶性肿瘤是肾移植后发病和死亡的主要原因。本回顾性研究调查了中国一家单一肾脏移植中心肾移植后新发恶性肿瘤的发生率和转归情况。
1989年至2010年期间,天津医科大学天津第一中心医院移植中心有1467例患者接受了肾脏移植。对肿瘤发生率、临床特征和转归数据进行了分析。还总结了文献综述。
1467例肾移植后,纳入了5名男性和9名女性(性别比为5:9)发生恶性肿瘤,平均年龄54岁(21 - 64岁),总体发生率为0.954%。泌尿系统恶性肿瘤是最常见的恶性肿瘤(57%)。术后肿瘤发生时间为1至133个月,平均值为42.78个月。其中4例死亡,死亡率为28.6%。
简而言之,随着移植患者数量的增加以及肾脏存活时间的延长,恶性肿瘤的发生将会增加。这就要求我们建立完善的移植随访体系,定期进行随访并仔细体检,不忽视肿瘤的任何早期特征,最终实现肿瘤的早期诊断和早期治疗,以提高肾移植术后恶性肿瘤的治愈率。